RxDoctor Payments Data

Yu-Po Lee, MD

Orthopaedic Surgery of the Spine · Orange, CANPI 1598780025

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Globus Medical accounts for 68.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $26,464 and has fallen 84.4% since, to $4,139 in 2025.

$62,901in general payments, 2019–2025

Across 67 payments — averaging $938.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$43K
  • Medical Device Business Services, Inc.$16K
  • Medacta USA, Inc.$2K
  • Medtronic$631
  • Orthofix Medical, Inc.$394
  • Abbott$285
  • plus $855 from 8 others
$77,030in research payments, 2019–2025

Across 27 payments — averaging $2852.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Orthofix Medical, Inc.$49K
  • Pfizer$28K

What the payments were for

  • Consulting fees$33,34453%
  • Speaking & faculty fees$20,02532%
  • Travel & lodging$5,9259%
  • Food & beverage$3,6086%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,901 in reported general payments places this provider in the 65th percentile of 288 orthopaedic surgery of the spine providers in California.

See all orthopaedic surgery of the spine providers in California →

Medicare billing

Part B allowed, 2024
$334,749
Medicare patients
530
Services billed
1,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl218$6,184
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen180$6,071
Lidocaine29$3,328
Gabapentin170$2,197
Celecoxib51$2,045
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen70$1,786
Naloxone Hcl22$1,037
Tramadol Hcl66$906
Cyclobenzaprine Hcl54$893
Morphine Sulfate ErMorphine Sulfate16$577
Methocarbamol55$552
Hydromorphone Hcl16$530
Diclofenac Sodium21$350
Tizanidine Hcl38$306
Zolpidem Tartrate50$281

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery of the spine in Orange

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →